{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349936","form_type":"8-K","ticker":"EIKN","cik":"0001861123","company_name":"Eikon Therapeutics, Inc.","filed_at":"2026-08-14T00:44:35+00:00","discovered_at":"2026-08-14T10:10:00.601918+00:00","generated_at":"2026-08-14T10:11:00.445189+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Eikon Therapeutics updates Q3 2026 corporate presentation; details not disclosed in filing","bullets":["Eikon Therapeutics (EIKN) furnished an updated Q3 2026 corporate presentation on August 13, 2026.","Exhibit 99.1 content is truncated in the filing; no financial, pipeline, or operational specifics are available.","CFO Alfred Bowie, Ph.D. signed the current report; no other material events are disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349936","json":"https://secwatch.observer/filing/0001193125-26-349936.json","markdown":"https://secwatch.observer/filing/0001193125-26-349936.md","text":"https://secwatch.observer/filing/0001193125-26-349936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526349936/0001193125-26-349936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526349936/eikn-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T10:11:00.445189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}